Document Detail

Penicillamine-induced proteinuria: risk factors.
MedLine Citation:
PMID:  3487119     Owner:  NLM     Status:  MEDLINE    
Twenty-six of 300 patients (9%) with rheumatoid arthritis (RA) developed penicillamine-induced proteinuria. The mean daily dose and duration of therapy at onset of proteinuria were 591 mg and 9 months, respectively, while the mean duration of proteinuria was 5.5 months. However, six patients developed proteinuria at 250 mg/d and six after 9 months of therapy. Twelve patients were successfully either restarted (five) or maintained (seven) on penicillamine with resolution of proteinuria. No permanent renal impairment occurred. Positive risk factors included the presence of HLA-B8 and DR3 and prior gold-induced proteinuria. Patients with prior gold-induced proteinuria should be observed more carefully, but tissue typing is not recommended as proteinuria is reversible. Furthermore, penicillamine can be restarted or maintained in these patients if the RA has responded favorably to the drug.
H B Stein; M L Schroeder; A M Dillon
Related Documents :
18258739 - Nephrotic state as a risk factor for developing posterior reversible encephalopathy syn...
6210069 - Mitomycin-induced hemolytic-uremic syndrome.
699399 - Rapidly progressive glomerulonephritis in adults: clinical and histologic correlations.
2182229 - Abnormally thin glomerular basement membrane and the goodpasture epitope.
22487479 - Patients with exocrine insufficiency due to chronic pancreatitis are undertreated: a du...
12727579 - Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment ...
21336239 - The clinical and radiological presentation of spinal dural arteriovenous fistula.
1732969 - Gray matter heterotopias: mr characteristics and correlation with developmental and neu...
2343369 - Cholecystostomy as a definitive operation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Seminars in arthritis and rheumatism     Volume:  15     ISSN:  0049-0172     ISO Abbreviation:  Semin. Arthritis Rheum.     Publication Date:  1986 May 
Date Detail:
Created Date:  1986-06-27     Completed Date:  1986-06-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1306053     Medline TA:  Semin Arthritis Rheum     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  282-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Rheumatoid / complications,  drug therapy,  immunology
Disease Susceptibility
HLA Antigens / analysis
HLA-B8 Antigen
HLA-DR3 Antigen
Histocompatibility Antigens Class II / analysis
Middle Aged
Penicillamine / adverse effects*,  therapeutic use
Proteinuria / chemically induced*
Reg. No./Substance:
0/HLA Antigens; 0/HLA-B8 Antigen; 0/HLA-DR3 Antigen; 0/Histocompatibility Antigens Class II; 52-67-5/Penicillamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
Next Document:  An acousto-optically steered laser scanning system for measurement of action potential spread in int...